BACKGROUND: Limited survival benefit and excess treatment because of prostate-specific antigen (PSA) screening in randomized trials suggests a need for more restricted selection of prostate biopsy candidates by discerning risk of histologically aggressive versus indolent cancer before biopsy. METHODS: Subjects undergoing first prostate biopsy enrolled in a multicenter, prospective cohort of the National Cancer Institute Early Detection Research Network (N = 635) were analyzed to develop a model for predicting histologically aggressive prostate cancers. The control arm of the Prostate Cancer Prevention Trial (N = 3833) was used to validate the generalization of the predictive model. RESULTS: The Early Detection Research Network cohort was comprised of men among whom 57% had no cancer, 14% had indolent cancer, and 29% had aggressive cancer. Age, body mass index, family history of prostate cancer, abnormal digital rectal examination (DRE), and PSA density (PSAD) were associated with aggressive cancer (all P < .001). The Early Detection Research Network model outperformed PSA alone in predicting aggressive cancer (area under the curve [AUC] = 0.81 vs 0.71, P < .01). Model validation in the Prostate Cancer Prevention Trial cohort accurately identified men at low (<10%) risk of aggressive cancer for whom biopsy could be averted (AUC = 0.78; 95% confidence interval, 0.75-0.80). Under criteria from the Early Detection Research Network model, prostate biopsy can be restricted to men with PSAD >0.1 ng/mL/cc or abnormal DRE. When PSAD is <0.1 ng/mL/cc, family history or obesity can identify biopsy candidates. CONCLUSIONS: A predictive model incorporating age, family history, obesity, PSAD, and DRE elucidates criteria whereby ¼ of prostate biopsies can be averted while retaining high sensitivity in detecting aggressive prostate cancer.
BACKGROUND: Limited survival benefit and excess treatment because of prostate-specific antigen (PSA) screening in randomized trials suggests a need for more restricted selection of prostate biopsy candidates by discerning risk of histologically aggressive versus indolent cancer before biopsy. METHODS: Subjects undergoing first prostate biopsy enrolled in a multicenter, prospective cohort of the National Cancer Institute Early Detection Research Network (N = 635) were analyzed to develop a model for predicting histologically aggressive prostate cancers. The control arm of the Prostate Cancer Prevention Trial (N = 3833) was used to validate the generalization of the predictive model. RESULTS: The Early Detection Research Network cohort was comprised of men among whom 57% had no cancer, 14% had indolent cancer, and 29% had aggressive cancer. Age, body mass index, family history of prostate cancer, abnormal digital rectal examination (DRE), and PSA density (PSAD) were associated with aggressive cancer (all P < .001). The Early Detection Research Network model outperformed PSA alone in predicting aggressive cancer (area under the curve [AUC] = 0.81 vs 0.71, P < .01). Model validation in the Prostate Cancer Prevention Trial cohort accurately identified men at low (<10%) risk of aggressive cancer for whom biopsy could be averted (AUC = 0.78; 95% confidence interval, 0.75-0.80). Under criteria from the Early Detection Research Network model, prostate biopsy can be restricted to men with PSAD >0.1 ng/mL/cc or abnormal DRE. When PSAD is <0.1 ng/mL/cc, family history or obesity can identify biopsy candidates. CONCLUSIONS: A predictive model incorporating age, family history, obesity, PSAD, and DRE elucidates criteria whereby ¼ of prostate biopsies can be averted while retaining high sensitivity in detecting aggressive prostate cancer.
Authors: Mark H Kawachi; Robert R Bahnson; Michael Barry; Peter R Carroll; H Ballentine Carter; William J Catalona; Jonathan I Epstein; Ruth B Etzioni; George P Hemstreet; Richard J Howe; Jeff D Kopin; Paul H Lange; Hans Lilja; James Mohler; Judd Moul; Robert B Nadler; Stephan Patterson; Alan Pollack; Joseph C Presti; Antoinette M Stroup; Donald A Urban; Robert Wake; John T Wei Journal: J Natl Compr Canc Netw Date: 2007-08 Impact factor: 11.908
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Joseph Feliciano; Ervin Teper; Michael Ferrandino; Richard J Macchia; William Blank; Ivan Grunberger; Ivan Colon Journal: J Urol Date: 2008-01-22 Impact factor: 7.450
Authors: Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei Journal: N Engl J Med Date: 2008-03-20 Impact factor: 91.245
Authors: Fei Dong; Michael W Kattan; Ewout W Steyerberg; J Stephen Jones; Andrew J Stephenson; Fritz H Schröder; Eric A Klein Journal: J Urol Date: 2008-05-15 Impact factor: 7.450
Authors: Marc A Dall'Era; Badrinath R Konety; Janet E Cowan; Katsuto Shinohara; Frank Stauf; Matthew R Cooperberg; Maxwell V Meng; Christopher J Kane; Nanette Perez; Viraj A Master; Peter R Carroll Journal: Cancer Date: 2008-06-15 Impact factor: 6.860
Authors: Monique J Roobol; Ewout W Steyerberg; Ries Kranse; Tineke Wolters; Roderick C N van den Bergh; Chris H Bangma; Fritz H Schröder Journal: Eur Urol Date: 2009-09-01 Impact factor: 20.096
Authors: Kathryn H Schmitz; Marian L Neuhouser; Tanya Agurs-Collins; Krista A Zanetti; Lisa Cadmus-Bertram; Lorraine T Dean; Bettina F Drake Journal: J Natl Cancer Inst Date: 2013-08-29 Impact factor: 13.506
Authors: Lora S Wang; Colin T Murphy; Karen Ruth; Nicholas G Zaorsky; Marc C Smaldone; Mark L Sobczak; Alexander Kutikov; Rosalia Viterbo; Eric M Horwitz Journal: Cancer Date: 2015-05-29 Impact factor: 6.860
Authors: Donna P Ankerst; Cathee Till; Andreas Boeck; Phyllis Goodman; Catherine M Tangen; Ziding Feng; Alan W Partin; Daniel W Chan; Lori Sokoll; Jacob Kagan; John T Wei; Ian M Thompson Journal: J Urol Date: 2013-01-09 Impact factor: 7.450
Authors: Haydn T Kissick; Seung T On; Laura K Dunn; Martin G Sanda; John M Asara; Kathryn L Pellegrini; Jonathan K Noel; Mohamed S Arredouani Journal: BMC Cancer Date: 2015-08-27 Impact factor: 4.430